Substance Dependence Clinical Trial
Official title:
An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of a 100mg Capsule Compared to Four 25mg GSK598809 Capsules and the Effect of Food on the Pharmacokinetics of the 100mg Capsule in Healthy Male and Female Volunteers.
Study to compare PK of a new 100mg capsule with four 25mg capsules. This is required because we plan to have only single capsules administered in the later phase clinical trials but we have not had a 100mg strength before. As this is a new previously untested strength we need to ensure that the PK is similar to that achieved using 4 x 25mg. The study will also assess the effect of high fat food on the PK of the 100mg capsule. The study is planned to consist of a single part , with three dosing periods, periods 1-3 consisting of 16 subjects. There will be a week wash out between each dose. In the three dosing periods subjects will either received 4x25 mg GSK598809 capsule in a fasted state, 100mg capsule in a fasted state or 100mg GSK598809 capsule in a fed state. Subjects will return to the centre for follow-up 7-14 days after the final dose. It is expected that the total duration of the study should be approximately eight weeks.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00887367 -
EtOH Interaction Study
|
Phase 1 | |
Completed |
NCT01036061 -
GSK618334 Repeat Dose Study
|
Phase 1 | |
Completed |
NCT01189799 -
Motivational Therapy for Substance Users With Depression
|
N/A | |
Completed |
NCT01381133 -
Adolescent Outpatient and Continuing Care Study
|
Phase 3 | |
Recruiting |
NCT04430257 -
Pre-exposure Prophylaxis (PrEP) for Health
|
N/A | |
Completed |
NCT01128140 -
Efficacy Trial of Warrior Check-Up
|
Phase 2 | |
Completed |
NCT03767907 -
Online Cognitive Behavioural Therapy for Addiction: Efficacy and Cost-Effectiveness in a Pragmatic Clinical Trial
|
N/A | |
Recruiting |
NCT05833399 -
Correlation of Genetic Variations With Clinical Response in Substance Use Disorder
|
||
Withdrawn |
NCT01515917 -
Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
|
N/A | |
Completed |
NCT00208143 -
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
|
Phase 4 | |
Withdrawn |
NCT03762798 -
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
|
N/A | |
Completed |
NCT03048552 -
Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3
|
N/A | |
Active, not recruiting |
NCT04768920 -
Examining Feasibility and Acceptability of Telemedicine for Substance Use Disorder (SUD)
|
N/A | |
Recruiting |
NCT05410561 -
Harnessing Telemedicine to Improve Alcohol Use Disorder Outcomes in Primary Care Patients
|
N/A | |
Recruiting |
NCT05679284 -
A Cross-Sectional Observational Study on Retained Drug Needle Fragments in People Who Use Intravenous Drugs
|
||
Withdrawn |
NCT00908206 -
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
|
Phase 1 | |
Recruiting |
NCT05348317 -
Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders
|
N/A | |
Recruiting |
NCT01741415 -
Distress Tolerance Treatment for Substance Users
|
Phase 2 | |
Active, not recruiting |
NCT01621711 -
Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care
|
N/A | |
Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 |